New Content  edit
Get The App!

Loading the player...
Biomarker and Surrogate Targets for Successful Therapy in Polycythemia Vera (PV)
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Serge Verstovsek MD, Richard Silver MD, Rubin Mesa MD, and Susan J. Leclair, PhD, CLS (NCA) discuss the roles of biomarkers and target levels in PV management. Maintaining hematocrit (Hct) level at or below 45% is a therapeutic target to reduce the risk of thrombosis in patients PV. Other hematologic findings may influence treatment goals, including Hct target, for individual patients.